Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H26FNO5 |
| Molecular Weight | 451.4867 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@@H](CC1=CC=C(OC)C(=C1)C(=O)NCC2=CC=C(OC3=CC=C(F)C=C3)C=C2)C(O)=O
InChI
InChIKey=VRHOBXXCNBZJRX-IBGZPJMESA-N
InChI=1S/C26H26FNO5/c1-3-19(26(30)31)14-18-6-13-24(32-2)23(15-18)25(29)28-16-17-4-9-21(10-5-17)33-22-11-7-20(27)8-12-22/h4-13,15,19H,3,14,16H2,1-2H3,(H,28,29)(H,30,31)/t19-/m0/s1
| Molecular Formula | C26H26FNO5 |
| Molecular Weight | 451.4867 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:12:51 GMT 2023
by
admin
on
Sat Dec 16 12:12:51 GMT 2023
|
| Record UNII |
V123C0BB32
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
311770-26-0
Created by
admin on Sat Dec 16 12:12:51 GMT 2023 , Edited by admin on Sat Dec 16 12:12:51 GMT 2023
|
PRIMARY | |||
|
9825046
Created by
admin on Sat Dec 16 12:12:51 GMT 2023 , Edited by admin on Sat Dec 16 12:12:51 GMT 2023
|
PRIMARY | |||
|
V123C0BB32
Created by
admin on Sat Dec 16 12:12:51 GMT 2023 , Edited by admin on Sat Dec 16 12:12:51 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Kyorin Pharmaceutical Co. Ltd.'s PPAR.ALPHA. agonist, KRP-101, has completed Phase IIa testing to treat dyslipidemia.
|
||
|
ACTIVE MOIETY |
The present study investigated the effects of a potent and subtype-selective PPARalpha agonist, KRP-101, in a nonrodent insulin-resistant animal model under pair-fed conditions. KRP-101 administration resulted in a significantly lower weight of overall visceral fat, which is associated with increased adiponectin and decreased leptin in serum. KRP-101 administration improved hyperglycemia and hyperinsulinemia as well as dyslipidemia in dogs fed a high-fat diet. Oral glucose tolerance test showed that KRP-101 administration improved glucose intolerance. The KRP-101 group showed a markedly lower hepatic triglyceride concentration.
|
